September 11, 2023
Satellos Biosciences; A potential small-cap DMD play
Coverage Universe
Satellos in Four Sentences: Satellos Biosciences is taking a completely novel approach to the treatment of a devastating degenerative muscle disease – Duchenne muscular dystrophy. The company’s lead candidate, SAT-3153, […]
May 1, 2023
Gain Therapeutics (Nasdaq: GANX)
Coverage Universe
Concise Investment Rationale Gain has an AI-enabled drug discovery platform, SEE-Tx, that is fast approaching having its first drug, GT-02287, enter human studies. GT-02287 has disease-modifying potential for a genetically […]
September 12, 2021
NervGen Pharma
Coverage Universe
NervGen is not an investment for the faint of heart, but for those investors who like to bet on trailblazing biotech companies with truly novel, disease modifying, science, and moonshot […]
June 7, 2021
Modular Medical
Coverage Universe
As the company “Pivots” from development to commercial stage, we believe shareholders could reap outsized returns. Read More.
November 9, 2020
Ocuphire Pharma
Coverage Universe
Low Science / High Science, Low Risk / High Risk, Ocuphire has a little of everything, heading into a data-rich 2021. Read More.
May 19, 2020
Delcath Systems
Coverage Universe
We believe Delcath’s $50mm market cap today is a reflection of its colorful past, not its bright future. Read More.
October 16, 2019
Xenon Pharma
Coverage Universe
We believe through clinical success with their lead assets, XEN496 and XEN1101, Xenon can achieve a market cap of >$1 billion by 2021, reflecting a nearly 4.5x multiple from its […]